Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side e...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 9; no. 4; pp. 2099 - 2104
Main Authors Tomizawa, Kento, Ando, Ken, Shimada, Hirofumi, Kaminuma, Takuya, Murata, Kazutoshi, Oike, Takahiro, Ohno, Tatsuya
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.04.2021
John Wiley and Sons Inc
Wiley
Subjects
Antigens
bevacizumab
Cancer therapies
Case Report
Case Reports
Cervical cancer
Cervix
Chemotherapy
dose‐volume analysis
Fistula
Gynecology
Lymphatic system
Metastasis
Patients
radiation
Radiation therapy
rectovaginal fistula
Rectum
Tumors
Vagina
United States > US
Sweden
bevacizumab
rectovaginal fistula
dose‐volume analysis
radiation
cervical cancer
Online AccessGet full text

Cover

More Information
Summary:Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum.
Bibliography:Funding information
The study was funded by Grants‐in‐Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan for programs for Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering. The study was also funded by Gunma University Heavy Ion Medical Center.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.3955